0001209191-23-024125.txt : 20230412
0001209191-23-024125.hdr.sgml : 20230412
20230412173602
ACCESSION NUMBER: 0001209191-23-024125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230410
FILED AS OF DATE: 20230412
DATE AS OF CHANGE: 20230412
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ballantyne Charles Evan
CENTRAL INDEX KEY: 0001371742
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40237
FILM NUMBER: 23816593
MAIL ADDRESS:
STREET 1: 27 HEARTHSTONE ROAD
CITY: HOPKINTON
STATE: MA
ZIP: 01748
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gain Therapeutics, Inc.
CENTRAL INDEX KEY: 0001819411
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851726310
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4800 HAMPDEN LANE
STREET 2: SUITE 200
CITY: BETHESDA
STATE: MD
ZIP: 20814
BUSINESS PHONE: (301) 500-1556
MAIL ADDRESS:
STREET 1: 4800 HAMPDEN LANE
STREET 2: SUITE 200
CITY: BETHESDA
STATE: MD
ZIP: 20814
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-10
0
0001819411
Gain Therapeutics, Inc.
GANX
0001371742
Ballantyne Charles Evan
C/O GAIN THERAPEUTICS, INC.
4800 MONTGOMERY LANE, SUITE 220
BETHESDA
MD
20814
0
1
0
0
Chief Financial Officer
0
Employee Stock Option (right to buy)
4.79
2023-04-10
4
A
0
100000
0.00
A
2033-04-10
Common Stock
100000
100000
D
Restricted Stock Units
2023-04-10
4
A
0
50000
0.00
A
Common Stock
50000
50000
D
The shares underlying the option shall vest 25% on April 10, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
The RSUs vest upon the board of directors' certification of the Issuer's share price reaching $10.00 per share based on the 10-day volume weighted average share price, subject to Reporting Person's continuous service through such vesting date.
/s/ Cathy Rude, Attorney-in-Fact
2023-04-12